Progressive Fibrosing Lung Disease Treated With Nintedanib in a Patient With Long‐Standing Autoimmune Pulmonary Alveolar Proteinosis: A Case Report
Case Reports in Pulmonology · 2026-01 · 2026 (1)
DOI: 10.1155/crpu/8073947 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Pulmonology, online erschienen am 31.07.2026. Verfasst von Yoshiaki Zaizen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan, kurume-u.a…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Autoimmune pulmonary alveolar proteinosis (APAP) is caused by impaired surfactant clearance due to neutralizing autoantibodies against granulocyte‐macrophage colony‐stimulating factor. Although whole‐lung lavage and inhaled granulocyte‐macrophage colony‐stimulating factor therapy are established treatment options, pulmonary fibrosis is increasingly recognized as a clinically relevant complication in a subset of patients with APAP. However, the clinical behavior of APAP‐associated fibrosing lung disease and the role of antifibrotic therapy remain unclear. Case Presentation A 54‐year‐old man with a 15‐year history of APAP was referred to our institution. High‐resolution computed tomography images obtained before referral showed slow progression of reticulation and traction bronchiectasis, suggesting fibrotic progression rather than recurrence of APAP. At presentation, forced vital capacity (FVC) was 3.31 L (80.0% predicted), and diffusion capacity for carbon monoxide (DL CO ) was preserved. During 6 months of observation, FVC declined to 3.03 L (73.5% predicted), accompanied by worsening dry cough and exertional dyspnea. Nintedanib was initiated for a progressive fibrosing phenotype in the context of APAP. Thereafter, FVC remained relatively stable for 2 years, whereas DL CO declined during follow‐up.
Conclusions
APAP‐associated fibrosing lung disease may present with a progressive fibrosing phenotype, but its diagnosis and management remain challenging. This case highlights the importance of distinguishing fibrotic progression from recurrence of intra‐alveolar proteinosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan, kurume-u.ac.jp.
- Department of Respiratory Medicine, Kirigaoka Tsuda Hospital, Kitakyushu, Fukuoka, Japan.
ORCID-Profile: Yoshiaki Zaizen, Tomoaki Hoshino
Zitieren
APA
Zaizen, Y., Nikaido, Y., Jimi, T., Kawano, T., Ichiki, K., Tsuda, T., & Hoshino, T. (2026). Progressive Fibrosing Lung Disease Treated With Nintedanib in a Patient With Long‐Standing Autoimmune Pulmonary Alveolar Proteinosis: A Case Report. Case Reports in Pulmonology, 2026(1). https://doi.org/10.1155/crpu/8073947
Vancouver
Zaizen Y, Nikaido Y, Jimi T, Kawano T, Ichiki K, Tsuda T, et al. Progressive Fibrosing Lung Disease Treated With Nintedanib in a Patient With Long‐Standing Autoimmune Pulmonary Alveolar Proteinosis: A Case Report. Case Reports in Pulmonology. 2026;2026(1). doi:10.1155/crpu/8073947
BibTeX
@article{Zaizen2026,
author = {Zaizen, Yoshiaki and Nikaido, Yasuhiko and Jimi, Takeo and Kawano, Tetsuya and Ichiki, Katsuyuki and Tsuda, Toru and Hoshino, Tomoaki},
title = {Progressive Fibrosing Lung Disease Treated With Nintedanib in a Patient With Long‐Standing Autoimmune Pulmonary Alveolar Proteinosis: A Case Report},
journal = {Case Reports in Pulmonology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crpu/8073947}
}
EUVIMED